« Previous
Next »
Titles
- Parks After Dark evaluation report2
- A healthy public needs more than public health: lessons for addressing substance use1
- A view of public health and biomedical research1
- Address Presented at a Special Hanukkah Convocation, Yeshiva University [Reminiscence]1
- Address Presented to the Annual Meeting of the NASA Occupational Health Program, San Antonio, Texas [Reminiscence]1
- Address Presented to the Health Reporting Conference of the American Medical Association, Boston, Massachusetts [Reminiscence]1
- Address Presented to the National Down Syndrome Congress, Cincinnati, Ohio [Reminiscence]1
- An Agenda for Public Health: Presented to the American Public Health Association, Boston, Massachusetts [Reminiscence]1
- Another call to go upstream: housing is health1
- Biodefense: federal efforts to develop biological threat awareness : report to Congressional requesters1
- Blueprint for a healthier America: modernizing the federal public health system to focus on prevention and preparedness1
- Blueprint for a healthier America: policy priorities for the next Administration and Congress1
- COVID-19: FDA took steps to help make tests available; policy for future public health emergencies needed : report to congressional addressees1
- California's public mental health services: how are older adults being served?1
- Centers For Disease Control and Prevention: use of special interest projects to fund prevention research centers : report to Congressional committees1
- Challenges to public health reporting experienced by non-federal acute care hospitals: 20191
- Changing health behaviors: reducing obesity by applying lessons learned from the campaign to control tobacco use1
- Charting a course for an equity-centered data system: recommendations from the National Commission to Transform Public Health Data Systems1
- Community perspectives: focus group findings on mental health : New York City Population Health Improvement Program : October 20181
- Considerations for the conduct of clinical trials of medical products during major disruptions due to disasters and public health emergencies: guidance for industry, investigators, and institutional review boards1